Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring
- PMID: 28302916
- DOI: 10.1042/CS20160196
Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring
Abstract
The purpose of this review is to provide an overview of diagnosis, prognosis and management of heart failure (HF) with reduced ejection fraction (HFrEF). Specifically, this review is divided into three sections. The first section will address biomarkers. The discovery of biomarkers has allowed further understanding of the pathophysiology of HF and provides insight into potential therapeutic targets. This review will focus on novel applications of natriuretic peptides (NPs) in clinical trials. Next, emerging biomarkers of HF, such as ST2, galectin-3 and copeptin, will be discussed. The second section aims to highlight HF therapies, including novel drugs and durable devices. The last section will review home haemodynamic monitoring and mobile health. We aim to provide context for the understanding of novel diagnostic and therapeutic advances in HF that are still in phase II or III trials, and have yet to become widely available.
Keywords: biomarker; emerging therapies; heart failure; personalized medicine; telemonitoring.
© 2017 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.
Similar articles
-
Biomarkers and diagnostics in heart failure.Biochim Biophys Acta. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014. Epub 2013 Jan 9. Biochim Biophys Acta. 2013. PMID: 23313577 Review.
-
MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.Eur J Heart Fail. 2015 Apr;17(4):405-15. doi: 10.1002/ejhf.244. Epub 2015 Mar 4. Eur J Heart Fail. 2015. PMID: 25739750 Free PMC article.
-
Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?Clin Chim Acta. 2015 Mar 30;443:9-16. doi: 10.1016/j.cca.2014.10.046. Epub 2014 Nov 15. Clin Chim Acta. 2015. PMID: 25447693 Review.
-
The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Curr Heart Fail Rep. 2013 Dec;10(4):441-9. doi: 10.1007/s11897-013-0169-1. Curr Heart Fail Rep. 2013. PMID: 24142671 Review.
-
Soluble ST2 in heart failure.Clin Chim Acta. 2015 Mar 30;443:57-70. doi: 10.1016/j.cca.2014.09.021. Epub 2014 Sep 28. Clin Chim Acta. 2015. PMID: 25269091 Review.
Cited by
-
Isovolumic loading of the failing heart by intraventricular placement of a spring expander attenuates cardiac atrophy after heterotopic heart transplantation.Biosci Rep. 2018 Jun 27;38(3):BSR20180371. doi: 10.1042/BSR20180371. Print 2018 Jun 29. Biosci Rep. 2018. PMID: 29743195 Free PMC article.
-
Prognostic value of interleukin-33, sST2, myeloperoxidase, and matrix metalloproteinase-9 in acute aortic dissection.Front Cardiovasc Med. 2023 Jan 6;9:1084321. doi: 10.3389/fcvm.2022.1084321. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36684579 Free PMC article.
-
Biomarkers in heart failure: the past, current and future.Heart Fail Rev. 2019 Nov;24(6):867-903. doi: 10.1007/s10741-019-09807-z. Heart Fail Rev. 2019. PMID: 31183637 Review.
-
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.Physiol Res. 2018 Jul 17;67(3):401-415. doi: 10.33549/physiolres.933757. Epub 2018 Mar 12. Physiol Res. 2018. PMID: 29527914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
